Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00459173 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Rimonabant as an Aid to Maintenance of Smoking Cessation
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,850
- Enrollment target
NCT00459173 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 4,850 participants.
The verdict
NCT00459173, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,850 participants
- Enrollment target
Study Summary
The primary study objective is to evaluate the efficacy of 2 dose levels of rimonabant (5 mg and 20 mg) for the maintenance of abstinence from smoking. Secondary objectives are to evaluate the effect of rimonabant on craving and weight, the clinical and biological safety of 2 doses of rimonabant rimonabant during a 12-month treatment period and to evaluate the pharmacokinetics of the drug.
Interventions
- DRUG rimonabant (SR141716)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,850 participants |
| Start Date | 2002-11 |
| Est. Completion | 2005-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00459173
The ClinicalTrials.gov registry entry for NCT00459173 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 4,850 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rimonabant (SR141716) is the first listed.
NCT00459173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00459173 about?
NCT00459173 is a clinical study titled "Efficacy and Safety of Rimonabant as an Aid to Maintenance of Smoking Cessation". The primary study objective is to evaluate the efficacy of 2 dose levels of rimonabant (5 mg and 20 mg) for the maintenance of abstinence from smoking. Secondary objectives are to evaluate the effect of rimonabant on craving and weight, the clinical and biological safety of 2 doses of rimonabant ri...
What is the current status of trial NCT00459173?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,850 participants. The study started on 2002-11. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00459173?
The interventions under investigation include: rimonabant (SR141716) (DRUG).
Who is sponsoring clinical trial NCT00459173?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.